Beta Bionics prices $150M public offering at $17.25/share

Beta Bionics Inc., a commercial-stage medical device company specializing in insulin delivery devices for people with diabetes, has announced the pricing of a $150 million public offering at $17.25 per share. The offering includes pre-funded warrants to purchase 1,043,484 shares at $17.2499 per share. The gross proceeds from the offering are expected to total $150 million before deducting underwriting discounts, commissions, and offering expenses.

The offering is expected to close on or about September 17, 2026, subject to customary closing conditions. The funds raised will be utilized for general corporate purposes, including the commercialization of Mint, expansion of manufacturing facilities, research and development, clinical development, and potential strategic opportunities.

J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners are acting as joint book-running managers for the offering.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.